Table 1. Baseline characteristics of the study participants according to fragility HF status.

Variables	Subjects without HF (n = 46)	Subjects with HF (n = 28)	P
Sex, no. (%)			0.603
Female	31 (67.4)	21 (75.0)
Male	15 (32.6)	7 (25.0)
Age (years)	72.1 ± 5.3	78.3 ± 9.1	0.002
Weight (kg)	58.2 ± 8.9	56.7 ± 11.7	0.552
Height (cm)	154.4 ± 8.0	155.0 ± 8.6	0.751
BMI (kg/m2)	24.4 ± 3.2	23.6 ± 4.4	0.379
Current smoker, no. (%)	7 (15.2)	4 (14.3)	0.999
Alcohol intake ≥ 3 U/day, no. (%)	8 (17.4)	3 (10.7)	0.518
Diabetes, no. (%)	9 (19.6)	3 (10.7)	0.517
Serum 25-OH-D3 (ng/mL)*	22.7 ± 15.3	18.3 ± 9.7	0.177
BMD:
Lumbar spine Z-score	0.642 ± 0.160	−0.358 ± 1.486	0.005
Femoral neck Z-score	0.973 ± 1.455	−0.329 ± 0.934	< 0.001
Total femur Z-score	0.534 ± 0.926	−0.643 ± 0.975	< 0.001
BTM:
CTX (ng/mL) *	0.535 ± 0.229	0.786 ± 0.349	0.002
Osteocalcin (ng/mL) *	19.9 ± 8.6	21.3 ± 10.2	0.524

Values are presented as mean ± SD unless otherwise specified. Bold means that values are statistically significant. ^*Serum CTX and OSC levels were measured using an electrochemical-luminescence immunoassay (Roche Diagnostics GmbH, Mannheim, Germany). Serum concentration of 25-OH-D3 was measured by radioimmunoassay (Cobra II Auto-γ Counting System; Packard Instruments, Downers Grove, IL).